Risks to mother, fetus and neonate from untreated Graves’ hyperthyroidism during gestation are compelling reasons for recommending pre-conception counselling. Pre-conception counselling should include discussion as to the optimum treatment of Graves’ hyperthyroidism in women wishing to become pregnant. Thyrotropin receptor antibodies remain elevated following radioiodine therapy, so medical or surgical treatment may be preferred to avoid fetal or neonatal hyperthyroidism. A TSH level <2.5 mIU/l must be achieved in women receiving LT4 before conception. The patient should be reassured that both she and the fetus can be maintained in a euthyroid state and that neonatal hyperthyroidism can be readily managed with a good outcome. The risks of antithyroid drug therapy during gestation should be fully discussed with emphasis on the very low risk (although real) of liver disease with propylthiouracil treatment and embryopathy with methimazole or carbimazole therapy. While propylthiouracil is the preferred drug for the first trimester, if it is not available other thionamides may be given. Breast-feeding while on antithyroid drugs is not contraindicated provided the dose of drug is low. The patient should also be advised of the importance of thyroid monitoring in the post-partum period.

1.
Lazarus JH: Thyroid function in pregnancy Br Med Bull 2011;97:137–148.
2.
Zuppa AA, Perrone S, Sindico P, Alighieri G, Antichi E, Carducci C, Romagnoli C: Fetal and neonatal outcomes in infants of mothers with TSH receptor antibody positivity in pregnancy. Pediatr Med Chir 2009;31:72–77.
3.
Tamaki H, Itoh E, Kaneda T, Asahi K, Mitsuda N, Tanizawa O, Amino N: Crucial role of serum human chorionic gonadotropin for the aggravation of thyrotoxicosis in early pregnancy in Graves’ disease. Thyroid 1993;3:189–193.
4.
Kung AW, Jones BM: A change from stimulatory to blocking antibody activity in Graves’ disease during pregnancy. J Clin Endocrinol Metab 1998;83:514–518.
5.
Amino N, Izumi Y, Hidaka Y, Takeoka K, Nakata Y, Tatsumi KI, Nagata A, Takano T: No increase of blocking type anti-thyrotropin receptor antibodies during pregnancy in patients with Graves’ disease. J Clin Endocrinol Metab 2003;88:5871–5874.
6.
Krassas GE, Poppe K, Glinoer D: Thyroid function and human reproductive health. Endocr Rev 2010;31:702–755.
7.
Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J: Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 2009;160:1–8.
8.
Mestman JH: Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab 2004;18:267–288.
9.
Casey BM, Leveno KJ: Thyroid disease in pregnancy. Obstet Gynecol 2006;108:1283–1292.
10.
Andersson M, de Benoist B, Delange F, Zupan J: Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2 years old: conclusions and recommendations of the technical consultation. Public Health Nutr 2007;10:1606–1611.
11.
Vanderpump MPJ, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K, Franklyn JA: Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 2011;377:2007–2012.
12.
Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN: The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673–674.
13.
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W: American Thyroid Association Taskforce on Thyroid Disease during Pregnancy and Postpartum: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081–1125.
14.
Marx H, Amin P, Lazarus JH: Pregnancy plus: hyperthyroidism and pregnancy. Br Med J 2008;336:663–667.
15.
McClain MR, Lambert-Messerlian G, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D’Alton ME, FaSTER Research Consortium: Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study. Am J Obstet Gynecol 2008;199:129.e1.
16.
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158:69–75.
17.
Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M: The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid 2007;17:767–772.
18.
Okamura K, Hagio N, Bandai S, Fujikawa M, Sato K, Iida M: The influence of pregnancy on the clinical course of Graves’ disease with special reference to the change in TSH receptor antibody and the long-term prognosis. International Thyroid Congress, Paris 2010, abstr. 0270.
19.
Azizi F, Amouzegar A: Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol 2011;164:871–876.
20.
Muller AF, Drexhage HA, Berghout A: Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: recent insights and consequences for antenatal and postnatal care. Endocr Rev 2001;22:605–630.
21.
Karras S, Tzotzas T, Kaltsas T, Krassas GE: Pharmacological treatment of hyperthyroidism during lactation: review of the literature and novel data. Pediatr Endocrinol Rev 2010;8:25–33.
22.
Ishikawa N: The relationship between neonatal developmental dysplasia of the hip and maternal hyperthyroidism. J Pediatr Orthop 2008;28:432–434.
23.
Amino N, Kubota S: Thyroid disease after pregnancy: postpartum thyroiditis; in Wass JA, Stewart PM (eds): Oxford Textbook of Endocrinology and Diabetes, ed 2. Oxford, Oxford University Press, 2011, pp 552–557.
24.
Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L: The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 2008;93:3985–3988.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.